Seladelpar
Seladelpar is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against peroxisome proliferator-activated receptor delta. In addition, it is known to target peroxisome proliferator-activated receptor gamma and peroxisome proliferator-activated receptor alpha.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
11 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hyperlipidemias | D006949 | EFO_0003774 | E78.5 | — | 1 | — | — | — | 1 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | 1 | — | — | — | 1 |
| Hyperlipoproteinemia type ii | D006938 | EFO_0004911 | E78.00 | — | 1 | — | — | — | 1 |
| Sclerosing cholangitis | D015209 | EFO_0004268 | K83.01 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatic insufficiency | D048550 | 2 | — | — | — | — | 2 | ||
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | SELADELPAR |
| INN | seladelpar |
| Description | Seladelpar (INN, USAN; developmental code names MBX-8025, RWJ-800025) is a PPARδ receptor agonist that is being investigated for drug use by Metabolex. According to a press release they are examining its potential use for the treatment of dyslipidemia, metabolic syndrome, type 2 diabetes, and non-alcoholic steatohepatitis (NASH). The compound was licensed from Janssen Pharmaceutica NV.
|
| Classification | Small molecule |
| Drug class | PPAR delta receptor agonists |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCO[C@H](COc1ccc(C(F)(F)F)cc1)CSc1ccc(OCC(=O)O)c(C)c1 |
Identifiers
| PDB | — |
| CAS-ID | 851528-79-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL230158 |
| ChEBI ID | — |
| PubChem CID | 11236126 |
| DrugBank | DB12390 |
| UNII ID | 7C00L34NB9 (ChemIDplus, GSRS) |
Target
Agency Approved
PPARD
PPARD
Organism
Homo sapiens
Gene name
PPARD
Gene synonyms
NR1C2, PPARB
NCBI Gene ID
Protein name
peroxisome proliferator-activated receptor delta
Protein synonyms
NUC1, NUCI, Nuclear hormone receptor 1, Nuclear receptor subfamily 1 group C member 2, Peroxisome proliferator-activated receptor beta, PPAR-beta, PPAR-delta, PPARD/MYO1D fusion
Uniprot ID
Mouse ortholog
Ppard (19015)
peroxisome proliferator-activated receptor delta (P37239)
Alternate
PPARG
PPARG
PPARA
PPARA
Organism
Homo sapiens
Gene name
PPARG
Gene synonyms
NR1C3
NCBI Gene ID
Protein name
peroxisome proliferator-activated receptor gamma
Protein synonyms
Nuclear receptor subfamily 1 group C member 3, peroxisome proliferator-activated receptor-gamma 5, peroxisome proliferator-activated receptor-gamma splicing, PPAR-gamma
Uniprot ID
Mouse ortholog
Pparg (19016)
peroxisome proliferator-activated receptor gamma (P37238)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 151 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more